From antibiotics to vaccines, medicines are no longer treated as ordinary goods. Governments are now treating pharmaceutical supply as a strategic asset, reshaping global supply chains and forcing Europe, the US and China into a new era of medical geopolitics.
The global medicine supply chain is no longer invisible
For decades, the pharmaceutical industry operated on a simple logic: produce where costs are lowest, ship globally, and rely on just‑in‑time logistics. That model is breaking down.
A large share of the world’s antibiotics and active pharmaceutical ingredients (APIs) is produced in China and India. This concentration was long seen as efficient. It is now seen as a vulnerability.
During the pandemic, Europe and the US experienced shortages of basic drugs — not only vaccines, but also painkillers, antibiotics and generic medicines. The shock revealed how fragile the system had become. It also exposed how little visibility governments had into the supply chains they depended on.
The lesson was simple: medicine is not just a market. It is infrastructure.
Covid changed how governments think about pharmaceuticals
Covid did not create the problem. It made it impossible to ignore.
When borders closed and factories shut down, governments realised they had no control over the production of essential medicines. They also discovered that supply chains were far more concentrated than expected.
The pandemic forced policymakers to ask a question that had rarely been asked before: What happens when a geopolitical crisis intersects with a medical one?
The answer was uncomfortable. Countries with domestic manufacturing capacity — or the ability to mobilise it quickly — fared better. Those without it faced shortages, export bans and political pressure.
The result is a global shift: pharmaceutical security is becoming a core part of national security.
The geopolitics of pharmaceuticals is now unavoidable
Medicines are becoming geopolitical for three reasons.
First, supply chains are concentrated in a small number of countries. China dominates the production of APIs. India dominates generics. This creates leverage — economic, political and strategic.
Second, biotechnology is becoming a frontier technology. It sits alongside AI, semiconductors and quantum computing as a domain where states want control, not dependence.
Third, governments are no longer willing to assume that global markets will function smoothly during crises. They want buffers, redundancy and domestic capacity.
This shift is visible across the world. The US is debating pharmaceutical reshoring and supply‑chain security.
China is rapidly expanding its biotech and pharmaceutical industries, aiming to become a global leader in biologics and advanced therapies.
And Europe — long reliant on global supply chains — is now rewriting its industrial policy.
Industrial policy returns: the new race for medical security
Pharmaceuticals were once seen as a mature industry. Now they are treated like semiconductors: strategic, sensitive and politically charged.
Governments are using tools once reserved for defence or energy:
- subsidies for domestic production
- strategic stockpiles
- reshoring incentives
- export controls
- “friend‑shoring” agreements
- public–private partnerships
The logic is clear. If medicines are essential, then relying on a single supplier — or a single region — is a risk no government wants to carry.
This is not de‑globalisation. It is re‑balancing. Countries want diversified supply, not total self‑sufficiency. But the direction of travel is unmistakable: more control, more visibility, more resilience.
Europe’s response: the Critical Medicines Act
Europe is moving faster than many expected. The EU is preparing the Critical Medicines Act, a sweeping plan to secure pharmaceutical supply and reduce dependence on China and India.
The Act aims to:
- identify “critical medicines”
- support EU‑based production
- create strategic stockpiles
- fast‑track “Strategic Projects”
- reform procurement rules
- coordinate shortages across member states
It is Europe’s most ambitious pharmaceutical policy in decades. It reflects a broader shift in Brussels: health security is now industrial policy.
The European Parliament has already backed the Act with overwhelming support. It is framed not only as a health measure, but as a response to geopolitical risk.
Europe’s challenge is scale. It has strong pharmaceutical companies, but its supply chains remain global and its regulatory environment is slow. The Critical Medicines Act is an attempt to change that — to build resilience without abandoning openness.
A new global race for pharmaceutical security
The geopolitics of medicine is still emerging, but the outlines are clear.
- The US wants to reshore production and reduce dependence on China.
- China wants to dominate biotech and become a global pharmaceutical power.
- India wants to remain the world’s generics hub.
- Europe wants resilience, diversification and strategic autonomy.
This is not a race for prestige. It is a race for security.
Medicines are becoming what energy was in the 1970s and what semiconductors are today: a strategic resource that governments cannot afford to lose control over.
The world is entering a new era — one where pharmaceutical policy, industrial strategy and geopolitics are inseparable.
Subscribe to EuroLuminant for independent European journalism.
